Email: cspc@cspc.cn
Media
News Center
Jun. 27
2023
VOLUNTARY ANNOUNCEMENT - CHINA'S FIRST ANTI-GFRAL MONOCLONAL ANTIBODY JMT203 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
VOLUNTARY ANNOUNCEMENT - TEDIZOLID PHOSPHATE FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF OMALIZUMAB FOR INJECTION
Jun. 26
Strategic Cooperation between CSPC and China Unicom
CSPC Listed in TOP 50 Global Pharmaceutical Companies Again
Presentation of CSPC’s Research Achievements as a Special Report at the International Stroke Conference
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
